EXD2 and cancer: Importantly, this phenotype could be recapitulated in BRCA1/2-deficient cancer cell lines (Dréan et al., 2017) (Figures 7D, 7E, S6G, and S6H) and is dependent on the nuclease activity of EXD2 (Figures 7F and S6I).